The estimated Net Worth of Perry Nisen is at least $2.04 Million dollars as of 15 June 2024. Mr. Nisen owns over 21,108 units of Teva- Pharmaceutical Industries stock worth over $1,718,467 and over the last 8 years he sold TEVA stock worth over $0. In addition, he makes $319,999 as Independent Director at Teva- Pharmaceutical Industries.
Perry has made over 7 trades of the Teva- Pharmaceutical Industries stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 21,108 units of TEVA stock worth $379,100 on 15 June 2024.
The largest trade he's ever made was exercising 21,108 units of Teva- Pharmaceutical Industries stock on 15 June 2024 worth over $379,100. On average, Perry trades about 6,379 units every 98 days since 2016. As of 15 June 2024 he still owns at least 95,683 units of Teva- Pharmaceutical Industries stock.
You can see the complete history of Mr. Nisen stock trades at the bottom of the page.
Dr. Perry D. Nisen M.D. Ph.D. serves as Independent Director of the Company. Mr. Nisen served as Chief Executive Officer and the Donald Bren Chief Executive Chair of Sanford Burnham Prebys Medical Discovery Institute. From 2004 to 2014, Dr. Nisen held various roles at GlaxoSmithKline, most recently as Senior Vice President, Science and Innovation. From 1997 to 2004, Dr. Nisen served as Divisional Vice President, Global Oncology Development, and as Divisional Vice President, Cancer Research, at Abbott Laboratories. Previously, he was the Lowe Foundation Professor of Neuro-Oncology at the University of Texas Southwestern Medical Center
As the Independent Director of Teva- Pharmaceutical Industries, the total compensation of Perry Nisen at Teva- Pharmaceutical Industries is $319,999. There are 17 executives at Teva- Pharmaceutical Industries getting paid more, with Kaare Schultz having the highest compensation of $11,596,600.
Perry Nisen is 64, he's been the Independent Director of Teva- Pharmaceutical Industries since 2017. There are 3 older and 25 younger executives at Teva- Pharmaceutical Industries. The oldest executive at Teva- Pharmaceutical Industries Ltd. is Gerald Lieberman, 73, who is the Independent Director.
Perry's mailing address filed with the SEC is C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, L3, 6944020.
Over the last 7 years, insiders at Teva- Pharmaceutical Industries have traded over $31,332,399 worth of Teva- Pharmaceutical Industries stock and bought 967,500 units worth $16,473,820 . The most active insiders traders include Sol J Barer, Tal Zvi Zaks, and Roberto Mignone. On average, Teva- Pharmaceutical Industries executives and independent directors trade stock every 9 days with the average trade being worth of $636,538. The most recent stock trade was executed by Varda Shalev on 2 September 2024, trading 12,872 units of TEVA stock currently worth $231,181.
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.
Teva- Pharmaceutical Industries executives and other stock owners filed with the SEC include: